Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Canadian Cancer Trials Group
Washington University School of Medicine
University of Southern California
Dana-Farber Cancer Institute
Providence Health & Services
National Institutes of Health Clinical Center (CC)
Xijing Hospital
M.D. Anderson Cancer Center
Vall d'Hebron Institute of Oncology
UNC Lineberger Comprehensive Cancer Center
Valo Therapeutics Oy
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Providence Health & Services
GC Cell Corporation
Acepodia Biotech, Inc.
UNC Lineberger Comprehensive Cancer Center
Spectrum Pharmaceuticals, Inc
Mayo Clinic
Shanghai Jiao Tong University School of Medicine
BioEclipse Therapeutics
Gilead Sciences
Leap Therapeutics, Inc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Roswell Park Cancer Institute
City of Hope Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fate Therapeutics
Hoffmann-La Roche
Aileron Therapeutics, Inc.
Columbia University
Fred Hutchinson Cancer Center
UMC Utrecht
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Technical University of Munich
AstraZeneca
Mayo Clinic
Washington University School of Medicine
University of Utah
Merrimack Pharmaceuticals
Shenzhen Second People's Hospital
Northwestern University
City of Hope Medical Center